Clorazepate use may prevent alcohol withdrawal convulsions.
Clorazepate dipotassium was administered orally for the five-day prophylactic treatment of potential, incipient and overt withdrawal signs and symptoms in 226 patients on admission to an inpatient alcohol treatment unit. Conservative estimates based on these patients' histories and on literature reports predicted that between 7 and 40 (3% to 18%) of these persons would be expected to have a withdrawal convulsion. No patients experienced convulsions. This complete absence of seizures suggests that clorazepate is effective in counteracting convulsive and other manifestations of the alcohol withdrawal syndrome.
D000284:Administration, Oral; D000430:Alcohol Withdrawal Delirium / Q000517:prevention & control*; D014151:Anti-Anxiety Agents / Q000627:therapeutic use*; D003009:Clorazepate Dipotassium / Q000627:therapeutic use*; D006801:Humans; D011604:Psychoses, Alcoholic / Q000517:prevention & control*; D012189:Retrospective Studies; D012640:Seizures / Q000517:prevention & control
D014151:Anti-Anxiety Agents; D003009:Clorazepate Dipotassium